Search Results
Your search for ,Inc matches 1253 pages
Showing 201 - 250Adjuvant Pembrolizumab May Improve Quality of Life in Patients With High-Risk Resected Melanoma
Taken together with the primary clinical results, a secondary analysis of the phase III SWOG S1404 randomized clinical trial demonstrated that pembrolizumab provides superior clinical and patient-reported quality-of-life outcomes compared to standard of care with adjuvant ipilimumab or high-dose...
Autologous Tumor Lysate–Loaded Dendritic Cell Vaccine for Glioblastoma
In an externally controlled phase III trial reported in JAMA Oncology, Liau et al found that the addition of an autologous tumor lysate–loaded dendritic cell vaccine (DCVax-L) to standard of care improved survival in patients with newly diagnosed glioblastoma and recurrent glioblastoma compared...
PALLAS Trial: No Benefit Reported for Adjuvant Palbociclib in Stage IIA Hormone Receptor–Positive, HER2-Negative Breast Cancer
In a preplanned analysis of the stage IIA cohort of the PALLAS trial, the addition of adjuvant palbociclib to standard endocrine therapy did not improve outcomes over endocrine therapy alone. This finding suggests this agent provides no benefit in reducing the risk of early relapse in patients with ...
Addition of Enzalutamide to Salvage Radiotherapy in Patients With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
In a phase II trial (SALV-ENZA) reported in the Journal of Clinical Oncology, Phuoc T. Tran, MD, PhD, and colleagues found that the addition of enzalutamide to salvage radiotherapy improved freedom from prostate-specific antigen (PSA) progression in patients with biochemically recurrent prostate...
Margetuximab-cmkb vs Trastuzumab With Chemotherapy in Previously Treated Advanced HER2-Positive Breast Cancer: Final Overall Survival Analysis of the SOPHIA Trial
As reported in the Journal of Clinical Oncology by Hope S. Rugo, MD, FASCO, and colleagues, the final overall survival results of the pivotal phase III SOPHIA trial have shown no significant difference between margetuximab-cmkb plus chemotherapy vs trastuzumab plus chemotherapy in previously...
Cemiplimab-rwlc in Combination With Platinum-Based Chemotherapy in Advanced NSCLC With No EGFR, ALK, or ROS1 Aberrations
On November 8, 2022, cemiplimab-rwlc was approved for use in combination with platinum-based chemotherapy for first-line treatment of patients with advanced non–small cell lung cancer (NSCLC) with no EGFR, ALK, or ROS1aberrations.1 Supporting Efficacy Data Approval was supported by findings in the...
Futibatinib for Cholangiocarcinoma With FGFR2 Gene Fusion or Other Rearrangements
On September 30, 2022, futibatinib was granted accelerated approval for adults with previously treated, unresectable, locally advanced, or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.1 Supporting Efficacy ...
Sodium Thiosulfate to Reduce the Risk of Cisplatin-Related Ototoxicity in Pediatric Patients With Localized Solid Tumors
On September 20, 2022, sodium thiosulfate was approved to reduce the risk of ototoxicity associated with cisplatin in pediatric patients (aged ≥ 1 month) with localized, nonmetastatic solid tumors.1 Supporting Efficacy Data Approval was based on findings in the multicenter open-label SIOPEL 6...
First-Line Pembrolizumab vs Chemotherapy in Advanced PD-L1–Positive NSCLC Without EGFR/ALK Alterations
As reported in the Journal of Clinical Oncology by Gilberto de Castro, Jr, MD, PhD, and colleagues, 5-year follow-up of the KEYNOTE-042 trial showed a maintained overall survival benefit with first-line pembrolizumab vs chemotherapy in patients with non–small cell lung cancer (NSCLC) with a PD-L1...
Lutetium Lu-177 Vipivotide Tetraxetan for PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
On March 23, 2022, the radioligand therapeutic agent lutetium Lu-177 vipivotide tetraxetan was approved for treatment of patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer who have been treated with an androgen receptor pathway inhibitor ...
Integrative Approaches to Managing Pain in Patients With Cancer: SIO-ASCO Guideline
Pain is highly prevalent in people with cancer throughout the disease trajectory. Often persisting for years after initial diagnosis and undertreated, it is associated with poor functional, mental, and cancer-related outcomes.1 Consequently, the need for effective pain management strategies has...
Ciltacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma
In a Chinese phase II trial (CARTIFAN-1) reported in the Journal of Clinical Oncology, Mi et al found that the anti–B-cell maturation antigen chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel was active in patients with relapsed or refractory multiple myeloma. Study Details...
Telisotuzumab Vedotin Plus Erlotinib in c-Met Protein–Expressing NSCLC
In a phase Ib trial reported in the Journal of Clinical Oncology, D. Ross Camidge, MD, PhD, and colleagues found that the combination of telisotuzumab vedotin and erlotinib showed activity in c-Met protein–expressing advanced non–small cell lung cancer (NSCLC), including those with an EGFR mutation ...
Researchers Discover Differences in Response to Pembrolizumab Among Patients With Endometrial Cancer
Researchers discovered a differential clinical response to pembrolizumab in patients with Lynch-like (mutated) vs methylated microsatellite instability–high endometrial cancer, outlining characteristics of patients who may derive benefit from immune checkpoint blockade antibodies, according to new...
Elacestrant Improves Progression-Free Survival vs Standard Endocrine Therapy in Previously Treated Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer
As reported in the Journal of Clinical Oncology by François-Clément Bidard, MD, PhD, of the Institut Curie, Paris and Saint Cloud, and colleagues, the phase III EMERALD trial has shown prolonged progression-free survival with the oral selective estrogen receptor degrader elacestrant vs standard...
Pembrolizumab With or Without Chemotherapy vs Cetuximab/Chemotherapy in Recurrent or Metastatic Head and Neck Cancer
As reported in the Journal of Clinical Oncology by Kevin Harrington, MD, PhD, and colleagues, updated results of the phase III KEYNOTE-048 trial showed enduring survival benefits with first-line pembrolizumab alone and pembrolizumab/chemotherapy vs cetuximab/chemotherapy in patients with recurrent...
DESTINY-Breast04 Trial: T-DXd Significantly Improves Survival in Patients With HER2-Low Metastatic Breast Cancer
The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) doubled progression-free survival compared with chemotherapy alone in patients with “HER2-low” metastatic breast cancer—ie, patients with low levels of HER2 expression. The agent also extended overall survival for patients with low ...
Enfortumab Vedotin-ejfv Plus Pembrolizumab in Cisplatin-Ineligible Patients With Advanced Urothelial Cancer
In a phase Ib/II study reported in the Journal of Clinical Oncology, Christopher J. Hoimes, MD, and colleagues found that first-line enfortumab vedotin-ejfv plus pembrolizumab produced a high response rate and prolonged response durations in cisplatin-ineligible, previously untreated patients with...
Ibrutinib for Pediatric Patients With Chronic Graft-vs-Host Disease
On August 24, 2022, ibrutinib was approved for pediatric patients 1 year of age or older with chronic graft-vs-host disease after failure of one or more lines of systemic therapy.1 A new oral suspension formulation is available. Supporting Efficacy Data Approval was based on findings from the...
Darolutamide Combined With Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
On August 5, 2022, darolutamide was approved for use in combination with docetaxel for patients with metastatic hormone-sensitive prostate cancer.1 Approval was based on the double-blind ARASENS trial (ClinicalTrials.gov identifier NCT02799602), in which 1,305 patients were randomly assigned to...
Addition of PD-1 Inhibitor Serplulimab to Chemotherapy in the First-Line Treatment of Extensive-Stage SCLC
As reported in JAMA by Cheng et al, an interim analysis of the phase III ASTRUM-005 trial has shown that the addition of the PD-1 inhibitor serplulimab to chemotherapy improved overall survival in the first-line treatment of patients with extensive-stage small cell lung cancer (SCLC). Study ...
Minimally Invasive vs Open Nephrectomy for Kidney Cancer: 1-Year Health-Care Expenditure and Utilization
In a retrospective cohort study reported in JAMA Network Open, Okhawere et al found that minimally invasive surgery was associated with similar or reduced total expenditures vs open surgery during the first year after partial or radical nephrectomy for kidney cancer. Study Details The study...
Overall Survival With Maintenance Olaparib in Newly Diagnosed Patients With Advanced BRCA-Mutated Ovarian Cancer: 7-Year Follow-up
As reported in the Journal of Clinical Oncology by DiSilvestro et al, the 7-year follow-up of the phase III SOLO1/GOG 3004 trial showed a reduction in risk of death by almost half with maintenance olaparib vs placebo in newly diagnosed patients with advanced ovarian cancer and a BRCA1/2 mutation,...
Pafolacianine for Intraoperative Imaging of Folate Receptor–Positive Ovarian Cancer
In a phase III trial reported in the Journal of Clinical Oncology, Janos L. Tanyi, MD, PhD, and colleagues found that use of pafolacianine infusion for intraoperative imaging improved the detection of lesions in patients with folate receptor–positive ovarian cancer, compared with using white light...
Preclinical Study Finds New Synthetic Lethal Agent Could Be Potential Treatment for Pancreatic Cancer
Researchers at The Marvin and Concetta Greenberg Pancreatic Cancer Institute at Fox Chase Cancer Center have found that a new synthetic lethal agent could be an effective treatment for pancreatic cancers with DNA damage repair (DDR) defects. Igor Astsaturov, MD, PhD, a co-director of the Institute...
Sequencing of Ipilimumab/Nivolumab With Encorafenib/Binimetinib in BRAF-Mutant Metastatic Melanoma
In a phase II trial (SECOMBIT) reported in the Journal of Clinical Oncology, Paolo A. Ascierto, MD, and colleagues found that sequential immunotherapy and targeted therapy with ipilimumab/nivolumab followed at disease progression by encorafenib/binimetinib was associated with good survival...
Updated Overall Survival Findings With Adjuvant Erlotinib vs Vinorelbine/Cisplatin in EGFR-Mutant Stage IIIA NSCLC
As reported in the Journal of Clinical Oncology by Yue et al, an updated analysis of the Chinese phase II EVAN study indicated a sizable overall survival advantage with adjuvant erlotinib vs vinorelbine/cisplatin in patients with R0 resected stage IIIA EGFR-mutant non–small cell lung cancer...
Neoadjuvant Cemiplimab in Patients With Stage II to IV Cutaneous Squamous Cell Carcinoma
In an international, multicenter phase II clinical trial, 63.3% of patients with stage II to IV cutaneous squamous cell carcinoma saw their tumors nearly or completely eradicated when treated with the anti–PD-1 agent cemiplimab-rwlc before surgery. The results were presented by Gross et al at the...
SWOG S1801: Neoadjuvant and Adjuvant Pembrolizumab for Patients With Stage IIIB to IV Melanoma
Patients with high-risk melanoma who received the anti–PD-1 therapy pembrolizumab both before and after surgery to remove cancerous tissue had a significantly lower risk of their cancer recurring than similar patients who received the drug only after surgery. These results from a study by the SWOG...
Thomas J. Herzog, MD, to Serve as Board President-Elect of the GOG Foundation, Inc, for Gynecologic Malignancies
The GOG Foundation, Inc (GOG-F), Board of Directors recently announced the election of Thomas J. Herzog, MD, as its next President, succeeding Larry J. Copeland, MD, who has served in this role since 2017. Under Dr. Copeland’s leadership, the GOG-F has experienced unprecedented growth in its...
Sacituzumab Govitecan in Pretreated Patients With Hormone Receptor–Positive, HER2-Negative Endocrine-Resistant Advanced Breast Cancer
As reported in the Journal of Clinical Oncology by Hope S. Rugo, MD, FASCO, and colleagues, the phase III TROPiCS-02 trial has shown a significant progression-free survival benefit with sacituzumab govitecan-hziy vs chemotherapy in previously treated patients with hormone receptor (HR)-positive,...
Adjuvant Pembrolizumab in Patients With Clear Cell Renal Cell Carcinoma and Increased Risk of Recurrence: 30-Month Follow-up of KEYNOTE-564
As reported in The Lancet Oncology by Thomas Powles, MD, PhD, and colleagues, the 30-month follow-up of the phase III KEYNOTE-564 trial showed a continued disease-free survival benefit with adjuvant pembrolizumab vs placebo in patients with clear cell renal cell carcinoma who are at increased risk...
BCMA x CD3 Bispecific T-Cell Redirecting Antibody ABBV-383 in Relapsed or Refractory Multiple Myeloma
In a phase I trial reported in the Journal of Clinical Oncology, D’Souza et al found that the B-cell maturation antigen (BCMA) x CD3 bispecific T-cell redirecting antibody ABBV-383 was active in patients with relapsed or refractory multiple myeloma. Study Details In the ongoing trial, 124 patients...
Addition of Telaglenastat to Cabozantinib in Previously Treated Patients With Metastatic Renal Cell Carcinoma
As reported in JAMA Oncology by Nizar M. Tannir, MD, FACP, and colleagues, the phase II CANTATA trial showed no improvement in progression-free survival with the addition of the glutaminase inhibitor telaglenastat to cabozantinib in previously treated patients with metastatic clear cell renal cell...
Luspatercept for Anemia in Patients With Lower-Risk Myelodysplastic Syndromes: Long-Term Follow-up
In a long-term follow-up of the German phase II PACE-MDS trial reported in the Journal of Clinical Oncology, Uwe Platzbecker, MD, and colleagues described erythroid, neutrophil, and platelet hematologic improvement rates with luspatercept treatment for anemia in patients with lower-risk...
Addition of T-VEC to Pembrolizumab in Advanced Melanoma
As reported in the Journal of Clinical Oncology by Chesney et al, the phase III MASTERKEY-265 trial has shown no significant improvement in progression-free survival or overall survival with the addition of talimogene laherparepvec (T-VEC) to pembrolizumab in patients with advanced melanoma. Study...
Researchers Outline a Path to Representation in Cancer Clinical Trials
A new study published by Birhiray et al in Blood Advances outlines practical strategies for promoting diversity, equity, inclusion, and access in cancer clinical research. The study highlights significant racial disparities in cancer research, citing that between 2008 and 2018, only 7.8% of...
Crizotinib in Adult and Pediatric ALK-Positive Inflammatory Myofibroblastic Tumors
On July 14, 2022, crizotinib was approved for adult and pediatric patients aged ≥ 1 year with unresectable, recurrent, or refractory ALK-positive inflammatory myofibroblastic tumors.1 Supporting Efficacy Data Approval was based on findings in the multicenter studies ADVL0912 (ClinicalTrials.gov...
FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients With Beta-Thalassemia Who Require Regular Blood Transfusions
On August 17, the U.S. Food and Drug Administration (FDA) approved betibeglogene autotemcel (Zynteglo), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions. “[This] approval is an important...
FDA Grants Accelerated Approval to Trastuzumab Deruxtecan for HER2-Mutant NSCLC
On August 11, 2022, the U.S. Food and Drug Administration (FDA) granted accelerated approval to fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for adult patients with unresectable or metastatic non–small cell lung cancer (NSCLC) whose tumors have activating HER2 mutations, as detected by an...
Older Age and Smoking Are the Most Important Risk Factors for Developing Any Cancer, Study Shows
A new large study led by researchers at the American Cancer Society (ACS) shows older age and smoking are the two most important risk factors associated with a relative and absolute 5-year risk of developing any cancer. The findings also demonstrate that in addition to age and smoking history,...
Lenvatinib Plus Pembrolizumab for Advanced Melanoma Progressing on PD-1/PD-L1 Inhibitor Therapy
In the phase II LEAP-004 trial reported in Journal of Clinical Oncology, Arance et al found that the combination of lenvatinib and pembrolizumab was active in patients with advanced melanoma with confirmed progression on PD-1/PD-L1 inhibitors as monotherapy or in combination with other agents. As...
Oral Paclitaxel Plus P-Glycoprotein Pump Inhibitor Encequidar vs Intravenous Paclitaxel in Metastatic Breast Cancer
In a Latin American phase III trial reported in the Journal of Clinical Oncology, Hope S. Rugo, MD, and colleagues found that oral paclitaxel with the P-glycoprotein pump inhibitor encequidar produced a higher response rate and trends toward better survival outcomes vs intravenous (IV) paclitaxel...
Maintenance Olaparib vs Placebo in Germline BRCA-Mutated Metastatic Pancreatic Cancer: Overall Survival Analysis of the POLO Trial
As reported in the Journal of Clinical Oncology by Hedy L. Kindler, MD, FASCO, and colleagues, the final overall survival analysis of the phase III POLO trial showed no significant difference between the maintenance olaparib group vs the placebo group in patients with germline BRCA-mutated...
CancerCare’s Caregiver Decision-Making Survey Results Reveal Gaps in Support for Caregivers, Give Rise to Recommendations for Improving Caregiver Support
CancerCare has released a report entitled “Cancer Caregivers: National Research Report on Shared Treatment Decision-Making.” It details the findings of its caregiver decision-making survey, which polled a nationally representative sample of 2,703 cancer caregivers between February and July 2021....
FDA Authorizes Emergency Use of Novavax COVID-19 Vaccine, Adjuvanted
On July 13, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the Novavax COVID-19 vaccine, adjuvanted, for the prevention of COVID-19 caused by SARS–CoV-2 in individuals aged 18 years and older. “Authorizing an additional COVID-19 vaccine expands the...
History of Radiation Oncology in the United States
Part 1 of this two-part report described the beginnings of radiation oncology in the United States, including many of the field’s early pioneers and the rise of associated professional societies. In part 2, we will consider the advances in technology and biology that are the foundation of modern...
ASCO’s CancerLinQ and HealthVerity Collaborate to Accelerate Cancer Research
On June 8, 2022, CancerLinQLLC, a wholly owned nonprofit subsidiary of ASCO, and HealthVerity, Inc., announced a collaboration that will create the nation’s premier real-world oncology data ecosystem to advance cancer care and research for government and public health agencies. The collaboration...
Cautious Optimism About Mining for Patient-Centric Data
“If we have data, let’s look at it. If all we have are opinions, let’s go with mine.” —James Barksdale In this issue of The ASCO Post, Daniel Vorobiof, MD, and Irad Deutsch, principles at Belong.Life, a patient-oriented website whose self-described mission is to improve patient quality of life and ...
Addition of Enzalutamide to Active Surveillance in Low- or Intermediate-Risk Localized Prostate Cancer
As reported in JAMA Oncology by Neal D. Shore, MD, FACS, and colleagues, the phase II ENACT trial has shown a reduced risk of disease progression with the addition of enzalutamide to active surveillance in patients with low- or intermediate-risk localized prostate cancer. Study Details In the...
